Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Background Replacement of the trivalent oral poliovirus vaccine (tOPV) with bivalent types 1 and 3 oral poliovirus vaccine (bOPV) and global introduction of inactivated poliovirus vaccine (IPV) are major steps in the polio endgame strategy. In this study, we assessed humoral and intestinal immunity in Latin American infants after three doses of bOPV combined with zero, one, or two doses of IPV. Methods This open-label randomised controlled multicentre trial was part of a larger study. 6-week-old full-term infants due for their first polio vaccinations, who were healthy on physical examination, with no obvious medical conditions and no known chronic medical disorders, were enrolled from four investigational sites in Colombia, Dominican Republic, Guatemala, and Panama. The infants were randomly assigned by permuted block randomisation (through the use of a computer-generated list, block size 36) to nine groups, of which five will be discussed in this report. These five groups were randomly assigned 1:1:1:1 to four permutations of schedule: groups 1 and 2 (control groups) received bOPV at 6, 10, and 14 weeks; group 3 (also a control group, which did not count as a permutation) received tOPV at 6, 10, and 14 weeks; group 4 received bOPV plus one dose of IPV at 14 weeks; and group 5 received bOPV plus two doses of IPV at 14 and 36 weeks. Infants in all groups were challenged with monovalent type 2 vaccine (mOPV2) at 18 weeks (groups 1, 3, and 4) or 40 weeks (groups 2 and 5). The p…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While virus shed by Sabin mOPV2 vaccinees isolated 7 days after vaccination caused paralysis in 90% of the mice in a neurovirulence assay (Asturias et al., 2016)”
From Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence (2020) · cites this paper as Asturias et al., 2016
Citations
Cites
Trained Immunity: A Memory for Innate Host Defense
Netea, M. G., Quintin, J., & van der Meer, J. W. M. (2011) · Cell Host & Microbe · doi:10.1016/j.chom.2011.04.006 · Cited by 1,682
Vaccines: Correlates of Vaccine‐Induced Immunity
Plotkin, S. A. (2008) · Clinical Infectious Diseases · doi:10.1086/589862 · Cited by 829
Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: Review.
Patriarca, P. A., Wright, P. F., & John, T. J. (1991) · Clinical Infectious Diseases · doi:10.1093/clinids/13.5.926 · Cited by 453
Polio vaccination: Past, present and future
Bandyopadhyay, A. S., Garon, J., Seib, K., & Orenstein, W. A. (2015) · Future Microbiology · doi:10.2217/fmb.15.19 · Cited by 276
Self-citationPlatt, L. R., Estivariz, C. F., & Sutter, R. W. (2014) · Journal of Infectious Diseases · doi:10.1093/infdis/jiu184 · Cited by 267
Trained immunity in newborn infants of HBV-infected mothers
Hong, M., Sandalova, E., Low, D., Gehring, A. J., Fieni, S., Amadei, B., Urbani, S., Chong, Y.-S., Guccione, E., & Bertoletti, A. (2015) · Nature Communications · doi:10.1038/ncomms7588 · Cited by 192
Herremans, T. M. P. T., Reimerink, J. H. J., Buisman, A. M., Kimman, T. G., & Koopmans, M. P. G. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.8.5011 · Cited by 149
Efficacy of inactivated poliovirus vaccine in India.
Krishnan, R., Jadhav, M., & John, T. J. (1983) · Europe PMC (PubMed Central) · Cited by 122
Efficacy of inactivated poliovirus vaccine in India
Jafari, H., Deshpande, J. M., Sutter, R. W., Bahl, S., Verma, H., Ahmad, M., Kunwar, A., Vishwakarma, R., Agarwal, A., Jain, S., et al. (2014) · Science · doi:10.1126/science.1255006 · Cited by 112
John, J., Giri, S., Karthikeyan, A. S., Iturriza-Gomara, M., Muliyil, J., Abraham, A., Grassly, N. C., & Kang, G. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60934-x · Cited by 109
Cited by
Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence
Yeh, M. T., Bujaki, E., Dolan, P. T., Smith, M., Wahid, R., Konz, J., Weiner, A. J., Bandyopadhyay, A. S., Van Damme, P., De Coster, I., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.04.003 · Cited by 221
Self-citationVan Damme, P., De Coster, I., Bandyopadhyay, A. S., Revets, H., Withanage, K., De Smedt, P., Suykens, L., Oberste, M. S., Weldon, W. C., Costa-Clemens, S. A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31279-6 · Cited by 141
Self-citationDe Coster, I., Leroux-Roels, I., Bandyopadhyay, A. S., Gast, C., Withanage, K., Steenackers, K., De Smedt, P., Aerssens, A., Leroux-Roels, G., Oberste, M. S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32541-1 · Cited by 86
Self-citationSáez-Llorens, X., Bandyopadhyay, A. S., Gast, C., Leon, T. D., DeAntonio, R., Jimeno, J., Caballero, M. I., Aguirre, G., Oberste, M. S., Weldon, W. C., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32540-x · Cited by 81
Self-citationMirzoev, A., Macklin, G. R., Zhang, Y., Mainou, B. A., Sadykova, U., Olsavszky, V. S., Huseynov, S., Ruziev, M., Saidzoda, F., Bobokhonova, M., et al. (2022) · The Lancet Global Health · doi:10.1016/s2214-109x(22)00412-0 · Cited by 30
Metadata
- Authors
- Asturias, E. J., Bandyopadhyay, A. S., Self, S., Rivera, L., Saez-Llorens, X., Lopez, E., Melgar, M., Gaensbauer, J. T., Weldon, W. C., Oberste, M. S., Borate, B. R., Gast, C., Clemens, R., Orenstein, W., O'Ryan G, M., Jimeno, J., Clemens, S. A. C., Ward, J., & Rüttimann, R.
- Affiliations
- Colorado School of Public Health (US)
- Gates Foundation (US)
- Fred Hutch Cancer Center (US)
- Roosevelt Hospital (GT)
- Centers for Disease Control and Prevention (US)
- Emory University (US)
- University of California, Los Angeles (US)
- Fighting Infectious Diseases in Emerging Countries (US)
- Corresponding author
- Asturias, Edwin J
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2016-07
- Volume
- 388
- Issue
- 10040
- Pages
- 158-169
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2396524001
- Cited by
- 80
- References
- 20
- Citations by year
- 2025: 3 · 2024: 3 · 2023: 4 · 2022: 8 · 2021: 7 · 2020: 10 · 2019: 9 · 2018: 11 · 2017: 17 · 2016: 8
- FWCI
- 12.38
- Type
- journal article
- Language
- en
- Open access
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Universidad de Chile (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
- Health Sciences › Medicine › Infectious Diseases › Viral gastroenteritis research and epidemiology
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- bivalent oral poliovirus vaccine, inactivated poliovirus vaccine, infant immunization, humoral immunity, intestinal immunity, neutralizing antibodies, seroconversion, trivalent oral polio vaccine, vaccine safety, adverse events
- MeSH terms
- Seroconversion, Colombia, Dominican Republic, Drug Therapy, Combination, Feces, Female, Guatemala, Humans, Immunization Schedule, Infant, Intestinal Mucosa, Latin America, Male, Panama, Poliomyelitis, Poliovirus Vaccine, Inactivated, Poliovirus Vaccine, Oral, Single-Blind Method, Virus Shedding, Immunity, Mucosal, Immunity, Humoral, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(16)00703-0
- The paper
- Asturias, E. J., Bandyopadhyay, A. S., Self, S., Rivera, L., Saez-Llorens, X., Lopez, E., Melgar, M., Gaensbauer, J. T., Weldon, W. C., Oberste, M. S., Borate, B. R., Gast, C., Clemens, R., Orenstein, W., O'Ryan G, M., Jimeno, J., Clemens, S. A. C., Ward, J., & Rüttimann, R. (2016). Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(16)00703-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.